The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Oral Antidiabetic Drugs Market Research Report 2025

Global Oral Antidiabetic Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1415052

No of Pages : 89

Ask Your Query

Synopsis

Oral antidiabetic drugs are medications used to manage blood glucose levels in individuals with type 2 diabetes. They work by improving insulin sensitivity, increasing insulin production, or reducing glucose production in the liver.

The global Oral Antidiabetic Drugs market was valued at US$ 1844 million in 2023 and is anticipated to reach US$ 2236.3 million by 2030, witnessing a CAGR of 3.1% during the forecast period 2024-2030.

The market for oral antidiabetic drugs is driven by the growing prevalence of type 2 diabetes and the need for effective and convenient glucose-lowering medications. The market's growth is also influenced by ongoing research in diabetes therapeutics, leading to the development of new drug classes and combination therapies.

This report aims to provide a comprehensive presentation of the global market for Oral Antidiabetic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Antidiabetic Drugs.

Report Scope

The Oral Antidiabetic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Antidiabetic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oral Antidiabetic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company (Partial List):

  • Eli Lilly
  • Abbott
  • Biocon
  • Sanofi
  • Sunpharma
  • Novartis
  • Novo Nordisk
  • Merck
  • Pfizer
  • Huadong Medicine Co.,Ltd.
  • Lepu Medical
  • Hengrui Medicine

Segment by Type

  • Sulfonylureas
  • Meglitinides
  • Alpha-glucosidase inhibitors

Segment by Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Antidiabetic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Antidiabetic Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Sulfonylureas
1.2.3 Meglitinides
1.2.4 Alpha-glucosidase inhibitors
1.3 Market by Application
1.3.1 Global Oral Antidiabetic Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oral Antidiabetic Drugs Market Perspective (2019-2030)
2.2 Oral Antidiabetic Drugs Growth Trends by Region
2.2.1 Global Oral Antidiabetic Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oral Antidiabetic Drugs Historic Market Size by Region (2019-2024)
2.2.3 Oral Antidiabetic Drugs Forecasted Market Size by Region (2025-2030)
2.3 Oral Antidiabetic Drugs Market Dynamics
2.3.1 Oral Antidiabetic Drugs Industry Trends
2.3.2 Oral Antidiabetic Drugs Market Drivers
2.3.3 Oral Antidiabetic Drugs Market Challenges
2.3.4 Oral Antidiabetic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral Antidiabetic Drugs Players by Revenue
3.1.1 Global Top Oral Antidiabetic Drugs Players by Revenue (2019-2024)
3.1.2 Global Oral Antidiabetic Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Oral Antidiabetic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oral Antidiabetic Drugs Revenue
3.4 Global Oral Antidiabetic Drugs Market Concentration Ratio
3.4.1 Global Oral Antidiabetic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Antidiabetic Drugs Revenue in 2023
3.5 Oral Antidiabetic Drugs Key Players Head office and Area Served
3.6 Key Players Oral Antidiabetic Drugs Product Solution and Service
3.7 Date of Enter into Oral Antidiabetic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral Antidiabetic Drugs Breakdown Data by Type
4.1 Global Oral Antidiabetic Drugs Historic Market Size by Type (2019-2024)
4.2 Global Oral Antidiabetic Drugs Forecasted Market Size by Type (2025-2030)
5 Oral Antidiabetic Drugs Breakdown Data by Application
5.1 Global Oral Antidiabetic Drugs Historic Market Size by Application (2019-2024)
5.2 Global Oral Antidiabetic Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oral Antidiabetic Drugs Market Size (2019-2030)
6.2 North America Oral Antidiabetic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oral Antidiabetic Drugs Market Size by Country (2019-2024)
6.4 North America Oral Antidiabetic Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oral Antidiabetic Drugs Market Size (2019-2030)
7.2 Europe Oral Antidiabetic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oral Antidiabetic Drugs Market Size by Country (2019-2024)
7.4 Europe Oral Antidiabetic Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oral Antidiabetic Drugs Market Size (2019-2030)
8.2 Asia-Pacific Oral Antidiabetic Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oral Antidiabetic Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Oral Antidiabetic Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oral Antidiabetic Drugs Market Size (2019-2030)
9.2 Latin America Oral Antidiabetic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oral Antidiabetic Drugs Market Size by Country (2019-2024)
9.4 Latin America Oral Antidiabetic Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral Antidiabetic Drugs Market Size (2019-2030)
10.2 Middle East & Africa Oral Antidiabetic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oral Antidiabetic Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Oral Antidiabetic Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Oral Antidiabetic Drugs Introduction
11.1.4 Eli Lilly Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Oral Antidiabetic Drugs Introduction
11.2.4 Abbott Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.2.5 Abbott Recent Development
11.3 Biocon
11.3.1 Biocon Company Detail
11.3.2 Biocon Business Overview
11.3.3 Biocon Oral Antidiabetic Drugs Introduction
11.3.4 Biocon Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.3.5 Biocon Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Oral Antidiabetic Drugs Introduction
11.4.4 Sanofi Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Sunpharma
11.5.1 Sunpharma Company Detail
11.5.2 Sunpharma Business Overview
11.5.3 Sunpharma Oral Antidiabetic Drugs Introduction
11.5.4 Sunpharma Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.5.5 Sunpharma Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Oral Antidiabetic Drugs Introduction
11.6.4 Novartis Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Detail
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Oral Antidiabetic Drugs Introduction
11.7.4 Novo Nordisk Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Merck
11.8.1 Merck Company Detail
11.8.2 Merck Business Overview
11.8.3 Merck Oral Antidiabetic Drugs Introduction
11.8.4 Merck Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.8.5 Merck Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Oral Antidiabetic Drugs Introduction
11.9.4 Pfizer Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Huadong Medicine Co.,Ltd.
11.10.1 Huadong Medicine Co.,Ltd. Company Detail
11.10.2 Huadong Medicine Co.,Ltd. Business Overview
11.10.3 Huadong Medicine Co.,Ltd. Oral Antidiabetic Drugs Introduction
11.10.4 Huadong Medicine Co.,Ltd. Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.10.5 Huadong Medicine Co.,Ltd. Recent Development
11.11 Lepu Medical
11.11.1 Lepu Medical Company Detail
11.11.2 Lepu Medical Business Overview
11.11.3 Lepu Medical Oral Antidiabetic Drugs Introduction
11.11.4 Lepu Medical Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.11.5 Lepu Medical Recent Development
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Detail
11.12.2 Hengrui Medicine Business Overview
11.12.3 Hengrui Medicine Oral Antidiabetic Drugs Introduction
11.12.4 Hengrui Medicine Revenue in Oral Antidiabetic Drugs Business (2019-2024)
11.12.5 Hengrui Medicine Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock